CClinicalTrials.gg
CompletedNCT01757821Updated Dec 2, 2017Results posted

Primed vs. Unprimed rTMS in Chronic Stroke

An interventional study of real 6-Hz primed low-frequency rTMS and Sham 6-Hz Primed low-frequency rTMS in Stroke, sponsored by University of Minnesota. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-02.

Sponsored by University of Minnesota · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of stroke rehabilitation is to restore function to the weak side of the body. However, this is often a difficult task to accomplish due to not only to damage from the stroke, but from increased excitability in the non-stroke side of the brain that inhibits the stroke side from functioning optimally. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive form of brain stimulation that can enhance excitability in the stroke side when applied at a low-frequency on the non-stroke side. By "inhibiting the inhibition" (i.e. disinhibition), rTMS promotes adaptive brain reorganization following stroke. Previous research in healthy individuals demonstrates enhanced effects of low-frequency rTMS when it is preceded by high-frequency (excitatory) rTMS stimulation known as priming. Our lab previously demonstrated the safety of 6-Hz priming with low-frequency rTMS in both adults and children with chronic stroke. However, it is currently unknown whether or not the addition of priming stimulation to low-frequency rTMS enhances excitability in the stroke hemisphere. Our study will examine three rTMS interventions in twelve adults (at least 18 years): 1.) 10 minutes of real priming followed by 10 minutes of low-frequency rTMS, 2.) 10 minutes of fake priming followed by 10 minutes of low-frequency rTMS, 3.) 20 minutes of low-frequency rTMS only. Participants will receive all three interventions in randomized order. Each week, participants will complete two pretest and 3 posttest sessions consisting of behavioral measures of weak upper extremity function and cortical excitability in addition to receiving one rTMS intervention. Following each week of testing and treatment, subjects will take a one week rest break before crossing-over to receive another intervention. We hypothesize the following: 1.) Primed rTMS will result in significantly reduced inhibition and significantly increased excitation on the stroke side vs. fake primed rTMS or low-frequency rTMS given alone and 2.) Primed rTMS will result in greater improvements of paretic hand function. This study is innovative in that it intends to compare primed and unprimed rTMS in the stroke brain that could acknowledge a more effective delivery method of rTMS to potentially yield greater rehabilitative outcomes.

Read the detailed description

Recovery following stroke is difficult not only because of the neuronal death from the ischemic insult but also because of maladaptive brain reorganization occurring from exaggerated inhibition imparted by the over-compensating contralesional primary motor area (M1) onto the ipsilesional M1 via transcallosal pathways. Advancement in stroke rehabilitation depends on innovative treatments like repetitive transcranial magnetic stimulation (rTMS) that possess the ability to disrupt this excessive inhibition. Through previous NIH/NICHD funding, my sponsor's research team confirmed the safety and efficacy of rTMS in both adult (1R01 HD053153-01A2) and children (1RC1 HD063838-01) with stroke using 6-Hz primed low-frequency rTMS applied to the contralesional M1 to produce disinhibition of the ipsilesional M1. With feasibility of primed rTMS now demonstrated, the proposed research plan will directly compare primed rTMS to unprimed rTMS. The investigators will investigate whether pretreatment of inhibitory low-frequency rTMS with excitatory high-frequency priming is more effective than sham-primed low-frequency rTMS in correcting the exaggerated interhemispheric inhibition acting on ipsilesional M1. While this may sound contradictory, the Bienenstock-Cooper-Munro theory of bidirectional plasticity supports this concept. The long-term goal is to discover the most effective rTMS protocol with which to safely up-regulate ipsilesional M1, rendering a more potent neuronal network for voluntary recruitment. By studying the efficacy of priming as measured by the amount of cortical excitability in both ipsilesional and contralesional hemispheres, a more advantageous delivery of rTMS may be realized and eventually incorporated into research trials and clinical practice. The study poses significant innovation as it explores the role of metaplasticity in rehabilitation using rTMS. The investigators will employ a double-blind crossover study using twelve adult participants with stroke. Because of heterogeneity in stroke type and location between subjects, a crossover design will reduce variability as each subject serves as their own control.

Specific Aim #1: Compare the effect of 6-Hz primed vs. unprimed low-frequency rTMS on cortical excitability in chronic stroke.Cortical excitability will be explored with TMS using ipsilesional paired-pulse testing, cortical silent period testing, and interhemispheric inhibition (IHI) paired-pulse testing.

Working hypotheses are:

  1. Primed rTMS will result in greater increases in the 3-ms and 15-ms ipsilesional paired-pulse to single-pulse (ipsilesional PP/SP) ratios than unprimed rTMS, indicating of decreased intracortical inhibition (GABAA-mediated) and greater intracortical facilitation, respectively.
  2. Primed rTMS will result in greater decreases than unprimed rTMS in duration of cortical silent period, indicating decreased inhibition (GABAB-mediated).
  3. Primed rTMS will result in a greater increase in the IHI PP/SP ratio in the non-stroke to stroke hemisphere direction and a corresponding decrease in the IHI PP/SP ratio in the stroke to non-stroke hemisphere direction than unprimed rTMS. This is consistent with less inhibition imparted onto the stroke hemisphere from the non-stroke hemisphere and greater inhibition imparted on the non-stroke hemisphere from the stroke hemisphere.

Specific Aim #2: Compare the effect of 6-Hz primed vs. unprimed low-frequency rTMS on functional outcome in chronic stroke. Functional outcome will be assessed by paretic hand performance on the Box and Block test.

Working hypothesis is:

  1. Primed rTMS will result in greater improvements on the Box and Block test.
02

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Stroke
  • rTMS
  • TMS
03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's enrollment of 11 is below the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

University of Minnesota is the lead sponsor of 1,184 studies on the registry; 195 are open to participants now.

Of its 132 completed or terminated interventional studies of FDA-regulated products, 91 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18 years of age or older
  • presence of stroke at least six months duration
  • demonstrate at least 10 degrees of active extension at the paretic index finger (metacarpophalangeal joint)
  • possess resting motor evoked potential on the stroke hemisphere with TMS testing
  • Upper Extremity Fugl Meyer score at least 20 out of 66
  • Beck Depression Inventory equal to or less than 19 out of 63
  • Mini-Mental State Examination score at least 24 out of 30
  • age-appropriate receptive language ability

Exclusion criteria

Exclusion Criteria:

  • history of seizure within the last two years
  • indwelling metal or medical devices incompatible with TMS
  • anosognosia
  • pregnancy
  • any co-morbidities impairing upper extremity function (e.g. fracture)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    6-Hz Priming

    real 6-Hz primed low-frequency rTMS

    Device: real 6-Hz primed low-frequency rTMS

  • Sham comparator
    Sham 6-Hz Priming

    Sham 6-Hz Primed low-frequency rTMS

    Device: Sham 6-Hz Primed low-frequency rTMS

  • Active comparator
    Real 1-Hz rTMS only

    real 1-Hz rTMS only

    Device: real 1-Hz rTMS only

Interventions

  • Devicereal 6-Hz primed low-frequency rTMS

    10 minutes of 6-Hz stimulation (real priming) followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region

  • DeviceSham 6-Hz Primed low-frequency rTMS

    10 minutes of sham priming stimulation followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region

  • Devicereal 1-Hz rTMS only

    20 minutes of low-frequency rTMS delivered to the nonstroke primary motor region

06

What researchers measure

Primary outcomes

  1. Change in Cortical Excitability: Paired-Pulse

    Cortical Excitability of the primary motor cortex on the stroke hemisphere will be assessed using paired-pulse transcranial magnetic stimulation.

    Time frame: Change from Baseline to 20 minutes

07

Results

Posted Dec 2, 2017

Participant flow

Participant flow — Overall Study
Milestone6-Hz Priming
Started11
Completed10
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryChange in Cortical Excitability: Paired-Pulse

Cortical Excitability of the primary motor cortex on the stroke hemisphere will be assessed using paired-pulse transcranial magnetic stimulation.

Time frame:
Change from Baseline to 20 minutes
Reported as:
Mean · milivolt
Change in Cortical Excitability: Paired-Pulse
milivoltReal 6-Hz PrimingSham 6-Hz PrimingReal 1-Hz rTMS Only
Change in Cortical Excitability: Paired-Pulse-18 ± 1418 ± 912 ± 5

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Real 6-Hz Priming—1/11 (9.1%)0/11 (0%)
Sham 6-Hz Priming—1/11 (9.1%)0/11 (0%)
Real 1-Hz rTMS Only—1/11 (9.1%)0/11 (0%)
Most frequent serious events
Most frequent serious events
EventReal 6-Hz PrimingSham 6-Hz PrimingReal 1-Hz rTMS Only
TumorNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/111/111/11

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Real 6-Hz Priming Sham 6-Hz Priming Real 1-Hz rTMS Only
<=18 years0
Between 18 and 65 years9
>=65 years2
Age, Continuous
Age, Continuous(years)Real 6-Hz Priming Sham 6-Hz Priming Real 1-Hz rTMS Only
Mean66 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Real 6-Hz Priming Sham 6-Hz Priming Real 1-Hz rTMS Only
Female3
Male8
Region of Enrollment
Region of Enrollment(participants)Real 6-Hz Priming Sham 6-Hz Priming Real 1-Hz rTMS Only
United States11
08

Study locations

1 site
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01757821
Lead sponsor
University of Minnesota
Responsible party
Sponsor
First posted
Dec 31, 2012
Start date
Apr 2013
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Dec 2, 2017
Last update
Dec 2, 2017

Study contacts

James R Carey, PhD, PT
principal investigator · University of Minnesota

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion